![Emma Tallantyre](https://profiles-cardiff.imgix.net/attachments/2615?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Emma Tallantyre
- Available for postgraduate supervision
Teams and roles for Emma Tallantyre
Reader, Division of Psychological Medicine and Clinical Neurosciences
Overview
I graduated from medical school at the University of Nottingham in 2002. I undertook my postgraduate medical and neurological training in Nottingham, Derby, Australia and South Wales. As an MRC research fellow, I completed a PhD investigating imaging (Sir Peter Mansfield MR centre) and neuropathology (Nottingham University) of multiple sclerosis (MS).
I have been involved in the clinical care of people with MS since 2006. I completed my clinical training in 2015 and became a Clinical Senior Lecturer in Neurology in 2018, and a Clinical Reader in 2022. I hold an honorary contract to work within the Helen Durham Neuroinflammatory Unit of the University Hospital of Wales. As part of this role I run weekly MS and general neurology clinics and contribute to service development.
My current research interests centre on the outcomes of neuroinflammatory disease. I am involved in clinical trials that investigate the optimum treatment approaches in multiple sclerosis. I have an interest in combining real world clinical data with associated biological and imaging data to strengthen predictions of outcome and improve trial design. I am also interested in the involvement of patients and the public in the development of clinical research studies.
Publication
2025
- Allen, C. M. et al., 2025. Comparison of the diagnostic performance of the central vein sign and CSF oligoclonal bands supporting the diagnosis of multiple sclerosis. Neurology Open Access 1 (2) e000021. (10.1212/wn9.0000000000000017)
- Androdias, G. et al., 2025. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain 148 (5), pp.1459-1478. (10.1093/brain/awae409)
- Davies, L. et al., 2025. Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis. Journal of Neurology 272 415. (10.1007/s00415-025-13133-w)
- Dobson, R. et al., 2025. Approach to JCV testing with natalizumab biosimilar: a UK consensus statement. Multiple Sclerosis and Related Disorders 100 106541. (10.1016/j.msard.2025.106541)
- Griffiths, L. et al., 2025. Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis. Brain Pathology 35 (5) e70001. (10.1111/bpa.70001)
- Tallantyre, E. C. et al. 2025. Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies. Multiple Sclerosis Journal 31 (8), pp.1007-1010. (10.1177/13524585251330962)
- Wood, C. et al., 2025. Multiple sclerosis and seizures: clinical, diagnostic and therapeutic correlations. Brain and Behavior 15 (5) e70511. (10.1002/brb3.70511)
2024
- Arun, T. et al., 2024. Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty. Multiple Sclerosis and Related Disorders 92 106144. (10.1016/j.msard.2024.106144)
- Coerver, E. et al., 2024. The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis. Multiple Sclerosis and Related Disorders 91 105900. (10.1016/j.msard.2024.105900)
- De Dios perez, B. et al., 2024. The Impact of Covid-19 on the employment of people with multiple sclerosis: A multi-methods study. International Journal of MS Care 26 (Q3), pp.174-186. (10.7224/1537-2073.2023-049)
- Gelissen, L. M. et al., 2024. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration. Multiple Sclerosis and Related Disorders 90 105796. (10.1016/j.msard.2024.105796)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
- Kreft, K. L. et al. 2024. Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort. Annals of Neurology 95 (3), pp.459-470. (10.1002/ana.26831)
- Nasir, M. et al., 2024. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders 85 105528. (10.1016/j.msard.2024.105528)
- Nicholas, R. et al., 2024. Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales. Journal of Neurology, Neurosurgery & Psychiatry 96 (11), pp.1032-1035. (10.1136/jnnp-2024-333532)
- Roos, I. et al., 2024. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal 30 (9), pp.1163-1175. (10.1177/13524585241267211)
- Tallantyre, E. C. et al. 2024. Real world persistence of multiple sclerosis disease modifying therapies. European Journal of Neurology 31 (7) e16289. (10.1111/ene.16289)
- Uzochukwu, E. C. et al. 2024. Modelling disease progression of Multiple Sclerosis in a South Wales cohort. Neuroepidemiology 58 (3), pp.218-226. (10.1159/000536427)
2023
- Garjani, A. et al., 2023. Decentralised clinical trials in multiple sclerosis research. Multiple Sclerosis Journal 29 (3), pp.317-325. (10.1177/13524585221100401)
- Harding, K. E. et al., 2023. Contemporary study of multiple sclerosis disability in South East Wales. Journal of Neurology, Neurosurgery and Psychiatry 94 (4), pp.272-279. (10.1136/jnnp-2022-330013)
- Htet, Z. M. and Tallantyre, E. 2023. Optic neuritis and MOGAD. Journal of Neurology 270 (6), pp.3278–3279. (10.1007/s00415-023-11738-7)
- Jacobs, B. M. et al., 2023. The ADAMS project - a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the United Kingdom. BMJ Open 13 e071656. (10.1136/bmjopen-2023-071656)
- Morgan, A. , Tallantyre, E. and Ontaneda, D. 2023. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Expert Review of Neurotherapeutics 23 (5), pp.433-444. (10.1080/14737175.2023.2208347)
- Papathanasiou, A. et al., 2023. Real world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: A retrospective multicentre cohort study. Neurological Sciences 44 , pp.3629-3635. (10.1007/s10072-023-06838-1)
- Zaloum, S. et al., 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29 (8), pp.979-989. (10.1177/13524585231185247)
2022
- Allman, M. , Tallantyre, E. and Robertson, N. P. 2022. Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies. Journal of Neurology 269 (4), pp.2259-2261. (10.1007/s00415-022-11053-7)
- Beesley, R. et al., 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68 104121. (10.1016/j.msard.2022.104121)
- Busse, M. et al. 2022. A web-based life-style, exercise and activity intervention for people with progressive multiple sclerosis results of a single-arm feasibility study. Multiple Sclerosis and Related Disorders 57 103388. (10.1016/j.msard.2021.103388)
- Cauchi, M. et al. 2022. Multiple Sclerosis and the risk of infection: Association of British Neurologists consensus guideline. Practical Neurology 22 (5), pp.344-357. (10.1136/practneurol-2022-003370)
- Garjani, A. et al., 2022. Mental health of people with multiple sclerosis during the COVID-19 outbreak: a prospective cohort and cross-sectional case-control study of the UK MS Register. Multiple Sclerosis Journal 28 (7), pp.1060-1071. (10.1177/13524585211020435)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91 (1), pp.89-100. (10.1002/ana.26251)
- Tallantyre, E. C. 2022. Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk ? No. Multiple Sclerosis Journal 28 (8), pp.1175-1177. (10.1177/13524585221091404)
- Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64 103937. (10.1016/j.msard.2022.103937)
- Topcu, G. et al., 2022. Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): Protocol for a mixed-methods, multi-centre feasibility randomised controlled trial. Pilot and Feasibility Studies 8 123. (10.1186/s40814-022-01073-5)
- Wood, C. H. et al. 2022. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. Multiple Sclerosis and Related Disorders 58 103492. (10.1016/j.msard.2022.103492)
2021
- Allen-Philbey, K. et al., 2021. Subcutaneous cladribine to treat multiple sclerosis: Experience in 208 patients. Therapeutic Advances in Neurological Disorders 14 , pp.1-16. (10.1177/17562864211057661)
- Busse, M. et al. 2021. A web-based physical activity intervention for people with progressive Multiple Sclerosis: application of consensus-based intervention development guidance. BMJ Open 11 (3) e045378. (10.1136/bmjopen-2020-045378)
- Chamberland, M. et al. 2021. Beyond lesion-load: tractometry-based metrics for characterizing white matter lesions within fibre pathways. Presented at: MICCAI 2020 International Workshop on Computational Diffusion MRI (CDMRI 2020) Virtual 8 October 2020. Published in: Gyori, N. et al., Computational Diffusion MRI: International MICCAI Workshop, Lima, Peru, October 2020. Mathematics and Visualization , pp.227-237. (10.1007/978-3-030-73018-5_18)
- Evangelou, N. et al., 2021. Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. Journal of Neurology, Neurosurgery and Psychiatry 92 , pp.107-109. (10.1136/jnnp-2020-324449)
- Fernandes, L. et al., 2021. The contemporary role of MRI in the monitoring and management of people with multiple sclerosis in the UK. Multiple Sclerosis and Related Disorders 55 103190. (10.1016/j.msard.2021.103190)
- Garjani, A. et al., 2021. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Multiple Sclerosis and Related Disorders 52 102939. (10.1016/j.msard.2021.102939)
- Hares, K. et al., 2021. KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology 268 , pp.2175-2184. (10.1007/s00415-020-10373-w)
- Latchem-Hastings, J. et al. 2021. Lifestyle, exercise and activity package for people living with progressive multiple sclerosis (LEAP-MS): protocol for a single-arm feasibility study. Pilot and Feasibility Studies 7 111. (10.1186/s40814-021-00852-w)
- Lipp, I. et al. 2021. Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: a behavioural and MRI study. Multiple Sclerosis 7 (7), pp.1088-1101. (10.1177/1352458520943788)
- MacIver, C. L. , Ebden, S. and Tallantyre, E. C. 2021. MRI: how to understand it. Practical Neurology 21 (3), pp.216-224. (10.1136/practneurol-2020-002905)
- Middleton, R. M. et al., 2021. COVID-19 in Multiple Sclerosis: clinically reported outcomes from the UK Multiple Sclerosis Register. Multiple Sclerosis and Related Disorders 56 103317. (10.1016/j.msard.2021.103317)
- Tallantyre, E. et al. 2021. Neurological updates: neurological complications of CAR-T therapy. Journal of Neurology 268 , pp.1544-1554. (10.1007/s00415-020-10237-3)
- Winter, M. et al. 2021. Tract-specific MRI measures explain learning and recall differences in multiple sclerosis. Brain Communications 3 (2) fcab065. (10.1093/braincomms/fcab065)
2020
- Allen, C. M. et al., 2020. Clinical observation during alemtuzumab administration. Multiple Sclerosis and Related Disorders 37 101412. (10.1016/j.msard.2019.101412)
- Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417 117079. (10.1016/j.jns.2020.117079)
- Lipp, I. et al. 2020. Tractography in the presence of multiple sclerosis lesions. NeuroImage 209 116471. (10.1016/j.neuroimage.2019.116471)
- Ontaneda, D. et al., 2020. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials 95 (10.1016/j.cct.2020.106009)
- Saxena, G. et al., 2020. Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis. Neurology, Neuroimmunology and Neuroinflammation 7 (4) e767. (10.1212/NXI.0000000000000767)
- Tallantyre, E. et al. 2020. Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. Multiple Sclerosis and Related Disorders 42 102056. (10.1016/j.msard.2020.102056)
- Tallantyre, E. et al. 2020. Achieving effective patient and public involvement in international clinical trials in neurology. Neurology 10 (3), pp.265-272. (10.1212/CPJ.0000000000000739)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26 (14), pp.1929-1937. (10.1177/1352458519887905)
2019
- Abdullah, A. A. N. and Tallantyre, E. 2019. HSV-2 radiculitis: An unusual presentation mere days after genital infection. Clinical Neurology and Neurosurgery 185 105429. (10.1016/j.clineuro.2019.105429)
- Castle, D. et al. 2019. Using biomarkers to predict clinical outcomes in multiple sclerosis. Practical Neurology 19 (4), pp.342-349. (10.1136/practneurol-2018-002000)
- Davda, N. , Tallantyre, E. and Robertson, N. P. 2019. Early MRI predictors of prognosis in multiple sclerosis. Journal of Neurology 266 (12), pp.3171-3173. (10.1007/s00415-019-09589-2)
- Harding, K. et al. 2019. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurology 76 (5), pp.536-541. (10.1001/jamaneurol.2018.4905)
- Lipp, I. et al. 2019. Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis. Human Brain Mapping 40 (10), pp.2917-2932. (10.1002/hbm.24568)
- Ontaneda, D. et al., 2019. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurology 18 (10), pp.973-980. (10.1016/S1474-4422(19)30151-6)
- Whittam, D. H. et al., 2019. Rituximab in neurological disease: principles, evidence and practice. Practical Neurology 19 (1), pp.5-10. (10.1136/practneurol-2018-001899)
2018
- Alsaeed, M. et al., 2018. Multiple sclerosis: long-term outcomes in ethnic minorities. analysis of a UK population-based registry. European Journal of Neurology 25 (4), pp.701-704. (10.1111/ene.13571)
- Beesley, R. et al., 2018. Impact of the 2017 revisions to McDonald criteria on the diagnosis of Multiple Sclerosis. Multiple Sclerosis 24 (13), pp.1786-1787. (10.1177/1352458518778007)
- Harding, K. et al. 2018. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple Sclerosis and Related Disorders 25 , pp.186-191. (10.1016/j.msard.2018.08.001)
- Robertson, J. and Tallantyre, E. 2018. Nerve sheath tumours. Journal of Neurology 265 (12), pp.3034-3035. (10.1007/s00415-018-9098-y)
- Tallantyre, E. et al. 2018. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. Journal of Neurology 265 (5), pp.1115-1122. (10.1007/s00415-018-8812-0)
- Tallantyre, E. C. , Robertson, N. P. and Jolles, S. 2018. Secondary antibody deficiency in neurology. Current Opinion in Allergy and Clinical Immunology 18 (6), pp.481-488. (10.1097/ACI.0000000000000485)
- Tallantyre, E. C. et al. 2018. How common is truly benign MS in a UK population?. Journal of Neurology, Neurosurgery and Psychiatry 90 , pp.522-528. (10.1136/jnnp-2018-318802)
2017
- Willis, M. et al. 2017. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neuroimmunology and Neuroinflammation 4 (2) E320. (10.1212/NXI.0000000000000320)
2016
- Tallantyre, E. C. and Robertson, N. P. 2016. Continuous evolution of magnetic resonance imaging in multiple sclerosis. Journal of Neurology 263 (4), pp.835-837. (10.1007/s00415-016-8099-y)
- Tallantyre, E. C. , Wardle, M. and Robertson, N. 2016. How to run a multiple sclerosis relapse clinic. Practical Neurology 16 (1), pp.62-69. (10.1136/practneurol-2015-001214)
2015
- Tallantyre, E. et al. 2015. The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic. Multiple Sclerosis Journal 21 (1), pp.67-75. (10.1177/1352458514538333)
- Tallantyre, E. C. and Robertson, N. 2015. Acute stroke management. Journal of Neurology 262 (1), pp.239-242. (10.1007/s00415-014-7607-1)
- Thomas, R. H. et al. 2015. Why neurology? The career choices of current UK neurology trainees [Conference Abstract]. Journal of Neurology, Neurosurgery & Psychiatry 86 (11), pp.e4. 042. (10.1136/jnnp-2015-312379.42)
- Williams, O. , Tallantyre, E. C. and Robertson, N. 2015. Traumatic brain injury: pathophysiology, clinical outcome and treatment. Journal of Neurology 262 (5), pp.1394-1396. (10.1007/s00415-015-7741-4)
2013
- Tallantyre, E. C. and Robertson, N. 2013. Autism and intellectual disability. Journal of Neurology 260 (3), pp.936-939. (10.1007/s00415-013-6861-y)
Articles
- Abdullah, A. A. N. and Tallantyre, E. 2019. HSV-2 radiculitis: An unusual presentation mere days after genital infection. Clinical Neurology and Neurosurgery 185 105429. (10.1016/j.clineuro.2019.105429)
- Allen, C. M. et al., 2020. Clinical observation during alemtuzumab administration. Multiple Sclerosis and Related Disorders 37 101412. (10.1016/j.msard.2019.101412)
- Allen, C. M. et al., 2025. Comparison of the diagnostic performance of the central vein sign and CSF oligoclonal bands supporting the diagnosis of multiple sclerosis. Neurology Open Access 1 (2) e000021. (10.1212/wn9.0000000000000017)
- Allen-Philbey, K. et al., 2021. Subcutaneous cladribine to treat multiple sclerosis: Experience in 208 patients. Therapeutic Advances in Neurological Disorders 14 , pp.1-16. (10.1177/17562864211057661)
- Allman, M. , Tallantyre, E. and Robertson, N. P. 2022. Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies. Journal of Neurology 269 (4), pp.2259-2261. (10.1007/s00415-022-11053-7)
- Alsaeed, M. et al., 2018. Multiple sclerosis: long-term outcomes in ethnic minorities. analysis of a UK population-based registry. European Journal of Neurology 25 (4), pp.701-704. (10.1111/ene.13571)
- Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417 117079. (10.1016/j.jns.2020.117079)
- Androdias, G. et al., 2025. De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain 148 (5), pp.1459-1478. (10.1093/brain/awae409)
- Arun, T. et al., 2024. Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty. Multiple Sclerosis and Related Disorders 92 106144. (10.1016/j.msard.2024.106144)
- Beesley, R. et al., 2018. Impact of the 2017 revisions to McDonald criteria on the diagnosis of Multiple Sclerosis. Multiple Sclerosis 24 (13), pp.1786-1787. (10.1177/1352458518778007)
- Beesley, R. et al., 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68 104121. (10.1016/j.msard.2022.104121)
- Busse, M. et al. 2021. A web-based physical activity intervention for people with progressive Multiple Sclerosis: application of consensus-based intervention development guidance. BMJ Open 11 (3) e045378. (10.1136/bmjopen-2020-045378)
- Busse, M. et al. 2022. A web-based life-style, exercise and activity intervention for people with progressive multiple sclerosis results of a single-arm feasibility study. Multiple Sclerosis and Related Disorders 57 103388. (10.1016/j.msard.2021.103388)
- Castle, D. et al. 2019. Using biomarkers to predict clinical outcomes in multiple sclerosis. Practical Neurology 19 (4), pp.342-349. (10.1136/practneurol-2018-002000)
- Cauchi, M. et al. 2022. Multiple Sclerosis and the risk of infection: Association of British Neurologists consensus guideline. Practical Neurology 22 (5), pp.344-357. (10.1136/practneurol-2022-003370)
- Coerver, E. et al., 2024. The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis. Multiple Sclerosis and Related Disorders 91 105900. (10.1016/j.msard.2024.105900)
- Davda, N. , Tallantyre, E. and Robertson, N. P. 2019. Early MRI predictors of prognosis in multiple sclerosis. Journal of Neurology 266 (12), pp.3171-3173. (10.1007/s00415-019-09589-2)
- Davies, L. et al., 2025. Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis. Journal of Neurology 272 415. (10.1007/s00415-025-13133-w)
- De Dios perez, B. et al., 2024. The Impact of Covid-19 on the employment of people with multiple sclerosis: A multi-methods study. International Journal of MS Care 26 (Q3), pp.174-186. (10.7224/1537-2073.2023-049)
- Dobson, R. et al., 2025. Approach to JCV testing with natalizumab biosimilar: a UK consensus statement. Multiple Sclerosis and Related Disorders 100 106541. (10.1016/j.msard.2025.106541)
- Evangelou, N. et al., 2021. Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. Journal of Neurology, Neurosurgery and Psychiatry 92 , pp.107-109. (10.1136/jnnp-2020-324449)
- Fernandes, L. et al., 2021. The contemporary role of MRI in the monitoring and management of people with multiple sclerosis in the UK. Multiple Sclerosis and Related Disorders 55 103190. (10.1016/j.msard.2021.103190)
- Garjani, A. et al., 2022. Mental health of people with multiple sclerosis during the COVID-19 outbreak: a prospective cohort and cross-sectional case-control study of the UK MS Register. Multiple Sclerosis Journal 28 (7), pp.1060-1071. (10.1177/13524585211020435)
- Garjani, A. et al., 2023. Decentralised clinical trials in multiple sclerosis research. Multiple Sclerosis Journal 29 (3), pp.317-325. (10.1177/13524585221100401)
- Garjani, A. et al., 2021. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Multiple Sclerosis and Related Disorders 52 102939. (10.1016/j.msard.2021.102939)
- Gelissen, L. M. et al., 2024. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration. Multiple Sclerosis and Related Disorders 90 105796. (10.1016/j.msard.2024.105796)
- Griffiths, L. et al., 2025. Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis. Brain Pathology 35 (5) e70001. (10.1111/bpa.70001)
- Harding, K. et al. 2018. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple Sclerosis and Related Disorders 25 , pp.186-191. (10.1016/j.msard.2018.08.001)
- Harding, K. et al. 2019. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurology 76 (5), pp.536-541. (10.1001/jamaneurol.2018.4905)
- Harding, K. E. et al., 2023. Contemporary study of multiple sclerosis disability in South East Wales. Journal of Neurology, Neurosurgery and Psychiatry 94 (4), pp.272-279. (10.1136/jnnp-2022-330013)
- Hares, K. et al., 2021. KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology 268 , pp.2175-2184. (10.1007/s00415-020-10373-w)
- Htet, Z. M. and Tallantyre, E. 2023. Optic neuritis and MOGAD. Journal of Neurology 270 (6), pp.3278–3279. (10.1007/s00415-023-11738-7)
- Jacobs, B. M. et al., 2023. The ADAMS project - a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the United Kingdom. BMJ Open 13 e071656. (10.1136/bmjopen-2023-071656)
- Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
- Kreft, K. L. et al. 2024. Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort. Annals of Neurology 95 (3), pp.459-470. (10.1002/ana.26831)
- Latchem-Hastings, J. et al. 2021. Lifestyle, exercise and activity package for people living with progressive multiple sclerosis (LEAP-MS): protocol for a single-arm feasibility study. Pilot and Feasibility Studies 7 111. (10.1186/s40814-021-00852-w)
- Lipp, I. et al. 2021. Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: a behavioural and MRI study. Multiple Sclerosis 7 (7), pp.1088-1101. (10.1177/1352458520943788)
- Lipp, I. et al. 2019. Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis. Human Brain Mapping 40 (10), pp.2917-2932. (10.1002/hbm.24568)
- Lipp, I. et al. 2020. Tractography in the presence of multiple sclerosis lesions. NeuroImage 209 116471. (10.1016/j.neuroimage.2019.116471)
- MacIver, C. L. , Ebden, S. and Tallantyre, E. C. 2021. MRI: how to understand it. Practical Neurology 21 (3), pp.216-224. (10.1136/practneurol-2020-002905)
- Middleton, R. M. et al., 2021. COVID-19 in Multiple Sclerosis: clinically reported outcomes from the UK Multiple Sclerosis Register. Multiple Sclerosis and Related Disorders 56 103317. (10.1016/j.msard.2021.103317)
- Morgan, A. , Tallantyre, E. and Ontaneda, D. 2023. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Expert Review of Neurotherapeutics 23 (5), pp.433-444. (10.1080/14737175.2023.2208347)
- Nasir, M. et al., 2024. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders 85 105528. (10.1016/j.msard.2024.105528)
- Nicholas, R. et al., 2024. Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales. Journal of Neurology, Neurosurgery & Psychiatry 96 (11), pp.1032-1035. (10.1136/jnnp-2024-333532)
- Ontaneda, D. et al., 2019. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurology 18 (10), pp.973-980. (10.1016/S1474-4422(19)30151-6)
- Ontaneda, D. et al., 2020. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials 95 (10.1016/j.cct.2020.106009)
- Papathanasiou, A. et al., 2023. Real world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: A retrospective multicentre cohort study. Neurological Sciences 44 , pp.3629-3635. (10.1007/s10072-023-06838-1)
- Robertson, J. and Tallantyre, E. 2018. Nerve sheath tumours. Journal of Neurology 265 (12), pp.3034-3035. (10.1007/s00415-018-9098-y)
- Roos, I. et al., 2024. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal 30 (9), pp.1163-1175. (10.1177/13524585241267211)
- Saxena, G. et al., 2020. Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis. Neurology, Neuroimmunology and Neuroinflammation 7 (4) e767. (10.1212/NXI.0000000000000767)
- Tallantyre, E. et al. 2020. Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. Multiple Sclerosis and Related Disorders 42 102056. (10.1016/j.msard.2020.102056)
- Tallantyre, E. et al. 2015. The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic. Multiple Sclerosis Journal 21 (1), pp.67-75. (10.1177/1352458514538333)
- Tallantyre, E. et al. 2020. Achieving effective patient and public involvement in international clinical trials in neurology. Neurology 10 (3), pp.265-272. (10.1212/CPJ.0000000000000739)
- Tallantyre, E. et al. 2021. Neurological updates: neurological complications of CAR-T therapy. Journal of Neurology 268 , pp.1544-1554. (10.1007/s00415-020-10237-3)
- Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91 (1), pp.89-100. (10.1002/ana.26251)
- Tallantyre, E. et al. 2018. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. Journal of Neurology 265 (5), pp.1115-1122. (10.1007/s00415-018-8812-0)
- Tallantyre, E. C. 2022. Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk ? No. Multiple Sclerosis Journal 28 (8), pp.1175-1177. (10.1177/13524585221091404)
- Tallantyre, E. C. et al. 2024. Real world persistence of multiple sclerosis disease modifying therapies. European Journal of Neurology 31 (7) e16289. (10.1111/ene.16289)
- Tallantyre, E. C. et al. 2025. Home-sampling of B cells using quantitative dried blood spots to enable tailored therapeutic re-dosing of anti-CD20 therapies. Multiple Sclerosis Journal 31 (8), pp.1007-1010. (10.1177/13524585251330962)
- Tallantyre, E. C. and Robertson, N. 2015. Acute stroke management. Journal of Neurology 262 (1), pp.239-242. (10.1007/s00415-014-7607-1)
- Tallantyre, E. C. and Robertson, N. 2013. Autism and intellectual disability. Journal of Neurology 260 (3), pp.936-939. (10.1007/s00415-013-6861-y)
- Tallantyre, E. C. , Robertson, N. P. and Jolles, S. 2018. Secondary antibody deficiency in neurology. Current Opinion in Allergy and Clinical Immunology 18 (6), pp.481-488. (10.1097/ACI.0000000000000485)
- Tallantyre, E. C. and Robertson, N. P. 2016. Continuous evolution of magnetic resonance imaging in multiple sclerosis. Journal of Neurology 263 (4), pp.835-837. (10.1007/s00415-016-8099-y)
- Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64 103937. (10.1016/j.msard.2022.103937)
- Tallantyre, E. C. , Wardle, M. and Robertson, N. 2016. How to run a multiple sclerosis relapse clinic. Practical Neurology 16 (1), pp.62-69. (10.1136/practneurol-2015-001214)
- Tallantyre, E. C. et al. 2018. How common is truly benign MS in a UK population?. Journal of Neurology, Neurosurgery and Psychiatry 90 , pp.522-528. (10.1136/jnnp-2018-318802)
- Thomas, R. H. et al. 2015. Why neurology? The career choices of current UK neurology trainees [Conference Abstract]. Journal of Neurology, Neurosurgery & Psychiatry 86 (11), pp.e4. 042. (10.1136/jnnp-2015-312379.42)
- Topcu, G. et al., 2022. Neuropsychological evaluation and rehabilitation in multiple sclerosis (NEuRoMS): Protocol for a mixed-methods, multi-centre feasibility randomised controlled trial. Pilot and Feasibility Studies 8 123. (10.1186/s40814-022-01073-5)
- Uzochukwu, E. C. et al. 2024. Modelling disease progression of Multiple Sclerosis in a South Wales cohort. Neuroepidemiology 58 (3), pp.218-226. (10.1159/000536427)
- Whittam, D. H. et al., 2019. Rituximab in neurological disease: principles, evidence and practice. Practical Neurology 19 (1), pp.5-10. (10.1136/practneurol-2018-001899)
- Williams, O. , Tallantyre, E. C. and Robertson, N. 2015. Traumatic brain injury: pathophysiology, clinical outcome and treatment. Journal of Neurology 262 (5), pp.1394-1396. (10.1007/s00415-015-7741-4)
- Willis, M. et al. 2017. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neuroimmunology and Neuroinflammation 4 (2) E320. (10.1212/NXI.0000000000000320)
- Winter, M. et al. 2021. Tract-specific MRI measures explain learning and recall differences in multiple sclerosis. Brain Communications 3 (2) fcab065. (10.1093/braincomms/fcab065)
- Wood, C. et al., 2025. Multiple sclerosis and seizures: clinical, diagnostic and therapeutic correlations. Brain and Behavior 15 (5) e70511. (10.1002/brb3.70511)
- Wood, C. H. et al. 2022. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. Multiple Sclerosis and Related Disorders 58 103492. (10.1016/j.msard.2022.103492)
- Zaloum, S. et al., 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29 (8), pp.979-989. (10.1177/13524585231185247)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26 (14), pp.1929-1937. (10.1177/1352458519887905)
Conferences
- Chamberland, M. et al. 2021. Beyond lesion-load: tractometry-based metrics for characterizing white matter lesions within fibre pathways. Presented at: MICCAI 2020 International Workshop on Computational Diffusion MRI (CDMRI 2020) Virtual 8 October 2020. Published in: Gyori, N. et al., Computational Diffusion MRI: International MICCAI Workshop, Lima, Peru, October 2020. Mathematics and Visualization , pp.227-237. (10.1007/978-3-030-73018-5_18)
Research
I have experience in using high field structural imaging to visualise white matter and grey matter pathology in the brains of people with MS. During my PhD I correlated in vivo MR imaging findings with the neurodegenerative pathology seen in the post mortem brains and spinal cords of those with longstanding MS.
My current research interests centre on the outcomes of neuroinflammatory disease. I am involved in clinical trials that investigate the optimum treatment approaches in multiple sclerosis. I contribute to a long running epidemiological project, prospectively collecting clinical data from a population-based cohort of people with neuroinflammatory diseases including MS. I have an interest in combining this real world clinical data with associated biological and imaging data to strengthen predictions of outcome and improve trial design. I am also interested in the involvement of patients and the public in the development of clinical research studies.
Grants and Awards
- Ferblanc. (Co-applicant) Diagnostic and predictive biomarkers in Neurosarcoidosis and Multiple Sclerosis: A prospective study. £20,000. Jan 2023 - Dec 2023.
- Academy of Medical Sciences. (Co-applicant) INSIPRE Scheme. £80,000. Feb 2023 - Feb 2025.
- Cardiff University, Research Infrastructure Award. (Lead applicant) Application for Simoa HD Analyser. £228,807. 2021 - 2022.
- Cardiff University, Research Infrastructure Award. (Co-applicant) Application for Array Coil for Sodium MR imaging. £157,600. 2021 - 2022.
- British Medical Association. (Lead Applicant). Immune responses to vaccination in people with MS. £63,857. August 2021 - 2022.
- MRC Confidence in Concept award. (Lead applicant). Diagnostic and predictive biomarkers in Multiple Sclerosis plasma: a comprehensive screening approach. £48,671 (100% to Cardiff). Dec 2019 – June 2021. 1h per week.
- Wellcome Institutional Strategic Support Funding Population award. (Lead applicant). Contemporary modelling of Multiple Sclerosis outcomes in a South Wales population. (Principal Applicant). £47,760 (100% received). Sept 2019 – Dec 2021. 0.5h per week.
- National Multiple Sclerosis Society (US) and UK MS Society; Joint Application for additional funds. Biobanking in Treatment Approach Studies in Relapsing Remitting Multiple Sclerosis. (Lead Applicant at sub-contracted site). £29,134 (100% to Cardiff). April 2019 – Dec 2022. 0.5h per week.
- National Institute for Health Research. DECISIve - DiagnosE using the Central veIn SIgn. A prospective diagnostic superiority study comparing T2* MRI and lumbar puncture in patients presenting with possible Multiple Sclerosis. (Co-applicant). £349,461 [£27,250 to Cardiff]. July 2019 – June 2022. 0.5h per week.
- Dowager Eleanor Peel Trust (Principal applicant) Serum Neurofilaments in multiple sclerosis. £9,936 (100% received). September 2018 – September 2019.
- Patient-Centred Outcome Research Institute (PCORI; co-applicant) 2017 - Determining the Effectiveness of Early Intensive versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS) -£7.5m.
- MS Society 2017 (co-applicant) - Life-style, Exercise and Activity Package for People living with Progressive Multiple Sclerosis (LEAP-MS) - £293,000.
- Health and Care Research Wales - Clinical Research Award 2016 - £67,927
- Wellcome Trust Institutional Strategic Support Fund Award (co-applicant) 2015 - £34,000
- Trainees Transforming Training 2015 - £5,000
- Biogen Idec MS Global Registry Fellowship 2014 - £62,000
- MRC Clinical Training Fellowship, 2007 - £100,000
- Peele Medical Trust, Research grant, 2006 - £5,000
Teaching
I contribute to the C21 Medical Undergraduate neurology teaching. I am clinical tutor to 4th year students rotating through Neurology placements and have also been undergraduate tutor to a group of 1st – 2nd year students since they entered the medical course.
I run a regular programme of 3rd and 4th year SSC projects as well as BSc intercalated projects for the undergraduate medical course. We receive consistently good feedback from our students and enjoy the interaction they bring to the department.
I organise teaching and training days for Neurology Specialty trainees across the region on subjects including Neuropathology, Neuroimaging and Neuro-oncology, with guest speakers and a range of formats.
I am examiner in undergraduate formative and summative pratical examinations (OSCE/ ISCE).
Biography
Academic and clinical positions
|
Clincial Reader |
Cardiff University |
August 2022 - present |
|
Clinical Senior Lecturer |
Cardiff University |
March 2018 - August 2022 |
|
Consultant Neurologist |
University Hospital of Wales |
March 2017 – Feb 2018 |
|
Clinical Senior Lecturer |
Cardiff University |
March 2016 – Feb 2017 |
|
Post-CCT Research Fellow
Neurology SpR |
University Hospital of Wales Wales Deanery |
July 2015 –Feb 2016
Aug 2012 – July 2015 |
|
Neurology SpR |
East Midlands Deanery |
August 2009 – August 2012 |
Professional memberships
- Member of Royal College of Physicians
- Association of British Neurology
- General Medical Council licence to practice
Committees and reviewing
I regularly review manuscripts for peer-reviewed publication.
I am a reviewer and have interviewed for grant awards via the Association of British Neurology.
I have also reviewed grant awards to MRC and MS Society.
Supervisions
I am interested in supervising PhD students in
Neuroinflammatory disease
Neuroimaging in MS
Engagement
I am involved in public engagament via various channels. We engage with our cohort of people with neuroinflamamtory disease via regular newsletters and patient information days. We have run numerous patient and stakeholder focus groups to guide and influence our research. I was involved in patient consultation during the development of the DELIVER-MS trial, including developing video media to aid consent. We published on metholodolgy, which was considered an exemplar for contemporary clinical trial engagement. I have provided public-facing information (Q&A) sessions on Facebook and Zoom Webinar. I am part of the Inspiring the Future scheme that seeks to promote STEM subjects for children.
